CHAIN Biotechnology Ltd, founded in 2014 by serial entrepreneur Dr. Edward Green, is making strides in the biotechnology sector with a focus on developing microbiome therapeutics. Its slogan, "Superior and effective microbiome therapeutics," captures its mission to harness the potential of Clostridia bacteria in the human gut microbiome.
The company has assembled an impressive technical team that includes experts in molecular biology, microbiology, and fermentation, leveraging additional expertise from the Synthetic Biology Research Centre at the University of Nottingham. Its proprietary Clostridium Assisted Drug Delivery (CADD™) platform is innovative, offering targeted drug delivery to the gut for clinical indications like localized infection and inflammation. Their lead asset targets Inflammatory Bowel Disease, a condition impacting millions globally.
Based in the United Kingdom, CHAIN recently secured a £1.80M Seed Round investment in July 2023, backed by investors including UK Innovation & Science Seed Fund and Future Planet Capital, showcasing strong market confidence in their pioneering approach.